Related Experiment Video

Updated: May 7, 2026

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software
07:32

Mast Cells in the Microenvironment of Hepatocellular Carcinoma Confer Favorable Prognosis: A Retrospective Study using QuPath Image Analysis Software

Published on: April 12, 2024

CD4+ CD28(null) cells are an independent predictor of mortality in patients with heart failure

Lorenz Koller1, Bernhard Richter, Georg Goliasch

  • 1Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Atherosclerosis
|October 1, 2013
PubMed

Insights

Elevated levels of CD4(+)CD28(null) cells in chronic heart failure (CHF) patients predict increased mortality. These immune cells are linked to CHF severity, highlighting the immune system

Area of Science:

  • Immunology
  • Cardiology
  • Pathophysiology

Background:

  • Immune activation and proinflammatory cytokines are key in chronic heart failure (CHF) pathophysiology.
  • CD4(+)CD28(null) cells, generated under inflammation, are linked to atherosclerosis and autoimmune diseases.

Purpose of the Study:

  • To investigate the prognostic impact of CD4(+)CD28(null) cells on survival in patients with chronic heart failure.

Main Methods:

  • Flow cytometry was used to analyze CD4 subsets in circulating lymphocytes from 107 CHF patients.
  • Median follow-up was 23 months, during which all-cause and cardiovascular mortality were recorded.

Main Results:

  • CD4(+)CD28(null) cells independently predicted all-cause mortality (HR 1.88) and cardiovascular mortality (HR 1.83).
  • A significant association was found between CD4(+)CD28(null) cells and NT-proBNP levels (r=0.23).

Conclusions:

  • Circulating CD4(+)CD28(null) cells are associated with CHF severity.
  • These cells are a strong, independent predictor of mortality in CHF patients.
  • The findings underscore the role of the immune system in CHF pathophysiology.
Abstract

Keywords:
CD4(+)CD28(null) cellsHeart failureImmune systemSurvival

More Related Videos

Isolation and Identification of Extravascular Immune Cells of the Heart08:24

Isolation and Identification of Extravascular Immune Cells of the Heart

Published on: August 23, 2018

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...